Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of GSK's Depemokimab?
Depemokimab is a monoclonal antibody commercialized by GSK, with a leading Phase III program in Hypereosinophilic Syndrome. According to Globaldata,...
Depemokimab by GSK for Asthma: Likelihood of Approval
Depemokimab is under clinical development by GSK and currently in Phase III for Asthma. According to GlobalData, Phase III drugs...
Depemokimab by GSK for Hypereosinophilic Syndrome: Likelihood of Approval
Depemokimab is under clinical development by GSK and currently in Phase III for Hypereosinophilic Syndrome. According to GlobalData, Phase III...